|
Palo Alto, CA, April 9, 2003 — Telik, Inc. (Nasdaq:
TELK) announced the identification of novel small molecule drug
candidates for important cancer targets through the application
of the company’s proprietary drug discovery technology, TRAP.
Several of these candidates resulted from collaborations between
Telik and leading cancer research centers. The studies were published
in the March 2003 Proceedings of the Annual Meeting of the American
Association for Cancer Research.
High efficiency screening: discovery of new cancer drug leads
with Telik’s TRAP technology (Abstract # 4576).
- PARG inhibitors: When DNA is damaged through the effects
of cancer chemotherapy or radiation therapy, PARG is upregulated
in order to protect the cell. Inhibition of PARG may provide benefit
in sensitizing cancer cells to treatment. Small molecule inhibitors
of PARG have been discovered through TRAP in a collaboration with
scientists at the University of Arizona Cancer Center (AZCC).
- Inhibitors of ß1 integrin-mediated cell adhesion.
Tumor cell adhesion to the extracellular matrix is an important
step in the spread of cancer. The ß1 integrins are receptor
proteins involved in adhesion and expressed in primary and metastatic
cancers. Inhibition of ß1 integrin activity may disrupt
adhesion and interfere with metastasis. Small molecule inhibitors
of ß1 integrins have been identified through TRAP in a collaboration
with scientists at AZCC.
- Inhibitors of human intestinal carboxylesterase (hiCE). The
chemotherapeutic drug irinotecan causes severe diarrhea due to
hiCE activation. A specific inhibitor of hiCE, used in combination
with irinotecan, might reduce this toxicity. TRAP has enabled
the identification of small molecule hiCE inhibitors which are
currently being assessed for in vivo activity in collaboration
with scientists at St. Jude Children’s Research Hospital.
Biochemical and cellular characterizations of c-Raf kinase inhibitors
discovered through TRAP technology (Abstract # LB-124).
- Raf kinase inhibitors. Mutations of the ras oncogene
are found in many tumor types and can lead to abnormal cell proliferation
through a pathway which includes Raf kinase. Small molecule inhibitors
of Raf kinase identified through TRAP have shown anti-proliferative
activity specific for cancer cells.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
serious diseases for which there is significant demand for new therapies.
The company’s most advanced drug development candidate is
TLK286, a tumor activated small molecule drug that is in a Phase
3 registration clinical trial in ovarian cancer and in clinical
trials in non-small cell lung, colorectal and breast cancer. TLK199
is in a Phase 1-2a trial in myelodysplastic syndrome, a form of
pre-leukemia. Telik’s product candidates were discovered
using its proprietary drug discovery technology, TRAP, which enables
the rapid and efficient discovery of small molecule drug candidates.
Additional information is available at www.telik.com.
You should not rely on forward-looking statements contained in
this press release, including statements regarding the ability of
our TRAP technology to generate additional drug candidates, or the
potential for TLK286 or TLK199 to treat one or more types of cancer.
Telik can give no assurance with regard to these statements. The
application of TRAP to additional new drug discovery may not yield
additional product candidates. TLK286 and TLK199 are in clinical
development and have not been approved for marketing, and there
can be no assurance that the clinical trials required to successfully
develop these compounds will have a successful outcome, or that
regulatory approval will be obtained. Telik is reliant on external
manufacturing of TLK286 and TLK199. More detailed information regarding
factors that may cause actual results to differ materially from
the results expressed or implied by statements in this press release
may be found in Telik’s periodic filings with the Securities
and Exchange Commission. Telik assumes no obligation to update any
information in this press release.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2003
Press Releases2004
Press ReleasesEvents
|
